# MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

> **NCT06097728** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 825 (estimated)

## Conditions studied

- Unresectable Pleural Mesothelioma

## Interventions

- **DRUG:** Volrustomig
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT06097728
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-09
- **Primary completion:** 2027-11-19
- **Final completion:** 2028-11-16
- **Target enrollment:** 825 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06097728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06097728, "MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06097728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*